Cas:1234616-66-0 [1,2,4]Triazolo[4,3-a]pyridine-7-carboxylic acid manufacturer & supplier

Chemical Name:[1,2,4]Triazolo[4,3-a]pyridine-7-carboxylic acid

CAS.NO:1234616-66-0

Synonyms:[1,2,4]Triazolo[4,3-a]pyridine-7-carboxylic acid;1,2,4-Triazolo[4,3-a]pyridine-7-carboxylic acid

Molecular Formula:C₇H₅N₃O₂

Molecular Weight:163.133

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.6±0.1 g/cm3

Index of Refraction:1.739

PSA:67.49000

Exact Mass:163.038177

LogP:0.36

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [1,2,4]Triazolo[4,3-a]pyridine-7-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,4-Triazolo[4,3-a]pyridine-7-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[1,2,4]Triazolo[4,3-a]pyridine-7-carboxylic acid Use and application,[1,2,4]Triazolo[4,3-a]pyridine-7-carboxylic acid technical grade,usp/ep/jp grade.

Related News: These sites operate under cGMP conditions and have been inspected and approved by leading global pharmaceutical companies and regulatory authorities, including the US FDA. 5-amino-3-methyl-1H-pyridin-2-one manufacturers The license, granted by the Medicines and Healthcare Products Regulatory Agency (MHRA), allows Onyx to support API projects from pre-clinical studies to low volume commercial manufacture. ethyl 2-hydroxy-3-phenylpropanoate suppliers The outlay will be used to grow Takeda’s portfolio of treatments and boost capacity to manufacture additional products for the rare disease community, Stephen Hatke, Takeda’s Thousand Oaks site head, said in a YouTube video about the expansion. The company didn’t name the specific products it plans to make there. Methyl 2-oxo-2H-cyclohepta[b]furan-3-carboxylate vendor & factory The license, granted by the Medicines and Healthcare Products Regulatory Agency (MHRA), allows Onyx to support API projects from pre-clinical studies to low volume commercial manufacture.,The outlay will be used to grow Takeda’s portfolio of treatments and boost capacity to manufacture additional products for the rare disease community, Stephen Hatke, Takeda’s Thousand Oaks site head, said in a YouTube video about the expansion. The company didn’t name the specific products it plans to make there.